Literature DB >> 16719832

Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents.

E Lech-Maranda1, A Korycka, T Robak.   

Abstract

More recently, three novel purine nucleoside analogs, including clofarabine, nelarabine and immucillin H, have been introduced into clinical trials. These agents have different metabolic properties, novel mechanism of action, and are undergoing phase I-II clinical studies for the treatment of hematopoietic malignancies. Pharmacology and anticancer activity of PNA are the subjects of this review.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16719832     DOI： 10.2174/138955706776876212

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  3 in total

1.  Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.

Authors:  Jamie J Arnold; Suresh D Sharma; Joy Y Feng; Adrian S Ray; Eric D Smidansky; Maria L Kireeva; Aesop Cho; Jason Perry; Jennifer E Vela; Yeojin Park; Yili Xu; Yang Tian; Darius Babusis; Ona Barauskus; Blake R Peterson; Averell Gnatt; Mikhail Kashlev; Weidong Zhong; Craig E Cameron
Journal:  PLoS Pathog       Date:  2012-11-15       Impact factor: 6.823

2.  Synthesis and anticancer activity of thiosubstituted purines.

Authors:  Alicja Kowalska; Małgorzata Latocha; Krystian Pluta
Journal:  Med Chem Res       Date:  2015-03-25       Impact factor: 1.965

3.  2,6-Di-chloro-9-(2',3',5'-tri-O-acetyl-β-d-ribo-furanos-yl)-9H-purine.

Authors:  Irina Novosjolova; Dmitrijs Stepanovs; Erika Bizdēna; Anatoly Mishnev; Māris Turks
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.